The Incannex Healthcare Limited (ASX: IHL) share price has hit a 5-year high at 29 cents during early trade. The shares have since retreated back to 26 cents, up 18%.
All the excitement comes after the company released an announcement this morning pertaining to an ongoing research program.
Positive results prompting further research
Incannex Healthcare is a pharmaceutical development company utilising medicinal cannabis and psychedelics to generate treatments for a range of disorders and diseases. In today’s update, Incannex discussed the positive results of using its proprietary anti-inflammatory IHL-675A in treating inflammatory bowel disease (IBD).
The company’s IHL-675A treatment is a combination of cannabidiol ‘CBD’ and hydroxychloroquine ‘HCQ’. As stated in the announcement, the pre-clinical in-vivo (in animal) study showed positive results when used to treat a mouse with a form of inflammatory bowel disease.
Furthermore, this result extends the possibilities of inflammatory treatments from the existing target indications shown for asthma, bronchitis, SAARDS, and COPD. Incannex accordingly highlighted the potential for IHL-675A to become a multi-use medication. The company has initiated its fifth research program following the promising results.
Where to from here for Incannex?
Incannex plans to now expand discussions with research organisations and regulators to press forward with clinical studies and a regulatory strategy. The company expects the Food and Drug Administration’s (FDA) new drug application pathway will be an available avenue for the inflammatory bowel disease indication.
According to the numbers supplied in the report, the IBD market is expected to reach US$22.4 billion by 2026. This will provide a large opportunity for any developments in the space.
Incannex share price snapshot
The Incannex share price has outperformed the market over the last year, netting shareholders a return of 324%. Most of those returns came about after September when the share price broke out above 7 cents.
Including today’s gains, the pharmaceutical developer now has a market capitalisation of $230 million.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
More reading
- Why the Incannex (ASX:IHL) share price is soaring 13%
- The Incannex (ASX:IHL) share price is surging 7% higher today. Here’s why
Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Why the Incannex Healthcare (ASX:IHL) share price is up 15% today appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/37ghnWY
Leave a Reply